Varenzin™-CA1 (molidustat oral suspension)
Provide your cat with comfort to help them feel more like their feline self with Varenzin-CA1 (molidustat oral suspension) – the only conditionally approved treatment for non-generative anemia associated with chronic kidney disease (CKD).
Help Improve Your Cat’s Quality of Life
If your cat has been diagnosed with anemia associated with CKD, it can be hard to watch them suffer, but a more comfortable life is possible with Varenzin-CA1.
Minimal Side Effects
Simple to Administer
Better Quality of Life
Treat CKD Related Anemia with Confidence
Control of nonregenerative anemia associated with chronic kidney disease.
Cats
Oral suspension
Once daily
Convenient At-Home Dosing
Varenzin-CA1 is a flavored liquid given once a day that’s simple to dose.
How to Administer:
STEP 1Shake well before use. Remove screw cap.
STEP 2Place the enclosed syringe nozzle firmly into the opening of the bottle.
STEP 3Turn the bottle upside down and withdraw the prescribed volume. Turn the bottle upright before removing the syringe.
STEP 4Administer directly into your cat’s mouth.
If your cat has been diagnosed with anemia associated with CKD, talk to your veterinarian about Varenzin-CA1.
Top Questions About Verenzin-CA1.
Varenzin, Elanco and the diagonal bar logo are trademarks of Elanco or its affiliates.
Indication
Varenzin-CA1 is indicated for the control of nonregenerative anemia associated with chronic kidney disease (CKD) in cats.
Important Safety Information
For oral use in cats only. Keep this drug, including used syringes, out of reach of children. Wash hands immediately after use. In case of accidental ingestion, seek medical advice immediately. Women who are pregnant or may become pregnant should administer the product with caution. Varenzin-CA1 should not be administered to cats that are pregnant, lactating or intended for breeding or to cats with known hypersensitivity to molidustat. Use with caution in cats with a history of seizures and in cats predisposed to thromboembolic disease. Hematocrit (HCT) or packed cell volume (PCV) levels should be monitored regularly as polycythemia may result from use of Varenzin-CA1. Varenzin-CA1 has not been evaluated in cats less than 1 year of age. The most common adverse reactions included vomiting, increases in systolic blood pressure and mild transient increase in serum potassium. Click here for full prescribing information.
